Clinical trial • Phase I | Phase III • Oncology
131I-TLX101 for Glioblastoma multiforme
Phase I | Phase III trial of 131I-TLX101 for Glioblastoma multiforme. 9 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Glioblastoma multiforme
- Trial Stage
- Phase I | Phase III
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 22-07-2024
- First CTIS Authorization Date
- 08-09-2024
Trial design
Phase I | Phase III trial across 4 sites in Austria, Netherlands.
- Target Sample Size
- 9
Recruitment
- Planned Sample Size
- 9
- Recruitment Window Months
- 52
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 9
Austria
- Earliest CTIS Part Ii Submission Date
- 06-08-2024
- Latest Decision Or Authorization Date
- 05-09-2025
- Processing Time Days
- 395
- Number Of Sites
- 2
- Number Of Participants
- 6
Sites
- Site Name
- Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken
- Department Name
- Klinische Abteilung für Onkologie
- Principal Investigator Name
- Matthias Preusser
- Principal Investigator Email
- matthias.preusser@meduniwien.ac.at
- Contact Person Name
- Matthias Preusser
- Contact Person Email
- matthias.preusser@meduniwien.ac.at
- Site Name
- Johannes Kepler University Linz
- Department Name
- Neuroonkologisches Zentrum
- Principal Investigator Name
- Josef Pichler
- Principal Investigator Email
- josef.pichler@kepleruniklinikum.at
- Contact Person Name
- Josef Pichler
- Contact Person Email
- josef.pichler@kepleruniklinikum.at
Netherlands
- Earliest CTIS Part Ii Submission Date
- 06-08-2024
- Latest Decision Or Authorization Date
- 25-09-2025
- Processing Time Days
- 415
- Number Of Sites
- 2
- Number Of Participants
- 3
Sites
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Radiology
- Principal Investigator Name
- Arthur Braat
- Principal Investigator Email
- a.j.a.t.braat@umcutrecht.nl
- Contact Person Name
- Arthur Braat
- Contact Person Email
- a.j.a.t.braat@umcutrecht.nl
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Radiology and Nuclear Medicine
- Principal Investigator Name
- Sophie Veldhuijzen van Zanten
- Principal Investigator Email
- s.veldhuijzenvanzanten@erasmusmc.nl
- Contact Person Name
- Sophie Veldhuijzen van Zanten
- Contact Person Email
- s.veldhuijzenvanzanten@erasmusmc.nl
Sponsor
Primary sponsor
- Full Name
- Telix Pharmaceuticals (Innovations) Pty Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Australia
Investigational products
- Investigational Product Name
- 131I-TLX101
- Modality
- Radiopharmaceutical
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- Itraconazole for Glioblastoma multiforme
- Pembrolizumab for Glioblastoma multiforme
- Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene for Glioblastoma multiforme
- BEVACIZUMAB for Glioblastoma multiforme
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer